CN117045531A - Gynecological lotion and preparation method and application thereof - Google Patents
Gynecological lotion and preparation method and application thereof Download PDFInfo
- Publication number
- CN117045531A CN117045531A CN202310853837.XA CN202310853837A CN117045531A CN 117045531 A CN117045531 A CN 117045531A CN 202310853837 A CN202310853837 A CN 202310853837A CN 117045531 A CN117045531 A CN 117045531A
- Authority
- CN
- China
- Prior art keywords
- gynecological lotion
- oligopeptide
- gynecological
- cyclohexylglycerol
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006210 lotion Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- XWZAWHJNTHSHGD-SIDOVBMKSA-N (2S)-6-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanamide Polymers CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccccc1)C(N)=O XWZAWHJNTHSHGD-SIDOVBMKSA-N 0.000 claims abstract description 39
- LOCUWELCCSIXGV-UHFFFAOYSA-N 1-cyclohexylpropane-1,2,3-triol Chemical compound OCC(O)C(O)C1CCCCC1 LOCUWELCCSIXGV-UHFFFAOYSA-N 0.000 claims abstract description 25
- 241000222122 Candida albicans Species 0.000 claims abstract description 14
- 229940095731 candida albicans Drugs 0.000 claims abstract description 14
- 230000005764 inhibitory process Effects 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 8
- OWTXHZITCDRRTI-UHFFFAOYSA-N 3-cyclohexyloxypropane-1,2-diol Chemical compound OCC(O)COC1CCCCC1 OWTXHZITCDRRTI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 42
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
- 235000011187 glycerol Nutrition 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- 239000003906 humectant Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 9
- 208000037888 epithelial cell injury Diseases 0.000 abstract description 3
- 230000002289 effect on microbe Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 239000003899 bactericide agent Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960002152 chlorhexidine acetate Drugs 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Abstract
The invention relates to the technical field of daily necessities, in particular to gynecological lotion and a preparation method and application thereof. The gynecological lotion comprises oligopeptide-10 and cyclohexylglycerol; the content of the oligopeptide-10 is 1-30ppm; the content of the cyclohexyl glycerin is 0.1% -0.3%; the solvent makes up 100%. The invention discovers that after oligopeptide-10 and cyclohexylglycerol are combined, the antibacterial effect is greatly improved, and the oligopeptide-10 can still have good inhibition effect on microorganism bacteria such as candida albicans under the condition that the dosage is lower than 50ppm. Meanwhile, the gynecological lotion provided by the invention has obvious advantages in cost because the dosage of the oligopeptide-10 is reduced. In addition, the gynecological lotion provided by the invention also has the effect of obviously repairing the vaginal epithelial cell injury.
Description
Technical Field
The invention relates to the technical field of daily necessities, in particular to gynecological lotion and a preparation method and application thereof.
Background
The gynecological lotion can be used for cleaning and maintaining daily private parts of women. The gynecological lotion commonly used in the market is mostly added with chemical bactericides such as chlorhexidine acetate or triclosan and the like. Although the gynecological lotion has good sterilization effect, the gynecological lotion has potential irritation and is not favored by consumers.
Staphylococcus aureus and candida albicans are common microorganisms that cause vaginal inflammation. In particular candida albicans, the large-scale propagation of which can damage vaginal epidermal cells. In trichomonas vaginalis, there is also similar damage to vaginal epithelial cells. At present, common gynecological lotions in the market generally have better antibacterial effect, but have less attention on vaginal epithelial cell repair and insignificant effect.
In view of this, the present invention has been made.
Disclosure of Invention
In order to solve the technical problems, the invention provides gynecological lotion and a preparation method and application thereof. The gynecological lotion not only has excellent antibacterial effect, but also has the effect of repairing vaginal epithelial cell injury.
Specifically, the technical scheme of the invention is as follows:
in a first aspect, the present invention provides a gynecological lotion comprising oligopeptide-10 and cyclohexylglycerol; the content of the oligopeptide-10 is 1-30ppm; the content of the cyclohexyl glycerin is 0.1% -0.3%; the solvent makes up 100%.
In the gynecological lotion commonly used in the market, chlorhexidine acetate or triclosan is often used as a bactericide, and the content of the bactericide is usually higher than 1000ppm, otherwise, the antibacterial effect on microorganisms, especially candida albicans is poor. However, the high content of the bactericide causes irritation of vaginal mucosa very easily.
The invention uses oligopeptide-10 and cyclohexylglycerol as the combined bactericide. Wherein the oligopeptide-10 has a bacteriostatic action, and the cyclohexylglycerol has a moisturizing and antiseptic synergistic action. The two can be combined to achieve excellent antibacterial rate with very little oligopeptide-10 dosage.
In the present invention, the oligopeptide-10 is contained in an amount of 1 to 30ppm, preferably 2 to 10ppm. The content of the cyclohexylglycerol is 0.1% -0.3%, preferably 0.2%.
Oligopeptide-10 is a synthetic polypeptide (pentadecapeptide) with reference to the amino acid sequence: phe-Ala-Lys-Lys-Leu-Ala-Lys-Leu-Ala-Leu-Lys-Leu-Ala-Lys-Leu is white powder at normal temperature and has a molecular weight of 1656.6. In general, oligopeptide-10 has an MIC of 5ppm for Staphylococcus aureus and Pseudomonas aeruginosa, 10ppm for Escherichia coli, and > 50ppm for Candida albicans.
The cyclohexylglycerol is a humectant, is not in the catalogue of preservatives for the quasi-cosmetics, has good antiseptic effect, but has weak bacteriostatic action for 2min, and the bacteriostatic rates are respectively as follows: the ratio of the strain to staphylococcus aureus ATCC6538 was 38.9%, the ratio of Escherichia coli 8099 was 43.2%, and the ratio of candida albicans ATCC10231 was 19.6%.
According to the invention, after the oligopeptide-10 and the cyclohexylglycerol are combined, the antibacterial effect is greatly improved, and the oligopeptide-10 can still have a good inhibition effect on candida albicans under the condition that the dosage is lower than 50ppm.
If oligopeptide-10 is singly used as a bactericide, and cyclohexylglycerol is not used, the antibacterial rate of candida albicans reaches more than 99.9 percent, and the content of the oligopeptide-10 is at least 50ppm.
The raw materials of the oligopeptide-10 are high in price, the oligopeptide-10 and the cyclohexylglycerol are compounded for use, the content of the oligopeptide-10 can be as low as 2ppm, and the raw material cost can be greatly reduced.
Meanwhile, the gynecological lotion provided by the invention also has a good effect of repairing the damaged cells of the epithelium.
In a preferred embodiment of the present invention, the oligopeptide-10 is present in an amount of 2 to 10ppm; the content of the cyclohexylglycerol is 0.2%.
More preferably, the oligopeptide-10 is present in an amount of 10ppm; the content of the cyclohexylglycerol is 0.2%.
Further, in the present invention, the gynecological lotion preferably further comprises at least one of a humectant and a pH adjuster.
Preferably, the humectant is selected from glycerin or other polyhydric alcohol type humectants, such as sorbitol, erythritol, xylitol, butylene glycol, and the like. When the humectant is selected from glycerin, the glycerin content is 1% to 5%, preferably 2% to 3%.
Preferably, the pH adjustor is selected from lactic acid; the pH value of the gynecological lotion is 4.0-4.3, and the gynecological lotion accords with the pH value of a normal vagina, and has no irritation in use.
In the present invention, the solvent is preferably water.
The source of each raw material of the gynecological lotion is not particularly limited, and the raw materials are commercially available in the field.
In a second aspect, the invention provides a method for preparing the gynecological lotion, comprising the following steps:
s1, weighing the components in proportion;
s2, mixing the components; the temperature of the mixing is less than or equal to 35 ℃.
In a more specific preferred embodiment provided by the invention, the preparation method of the gynecological lotion comprises the following steps:
heating purified water as solvent to 90-95deg.C, maintaining the temperature for 30min, sterilizing at high temperature, cooling to below 35deg.C, sequentially adding glycerol, cyclohexylglycerol, and oligopeptide-10 powder, stirring to uniformity, adding lactic acid, and adjusting pH to 4.0-4.3.
In a third aspect, the invention provides the gynecological lotion, or the application of the gynecological lotion prepared by the preparation method in bacteriostasis and/or repair of epithelial damaged cells for non-disease treatment purposes.
Preferably, the inhibition comprises inhibition of at least one of the following microbial species: staphylococcus aureus, escherichia coli, candida albicans.
Preferably, the means of bacteriostasis comprises inhibition of microbial bacteria in the environment; alternatively, repairing the epithelial damaged cell comprises repairing the epithelial damaged cell during cell culture.
The beneficial effects are that:
the invention provides gynecological lotion and a preparation method and application thereof. The gynecological lotion comprises oligopeptide-10 and cyclohexylglycerol; the content of the oligopeptide-10 is 1-30ppm; the content of the cyclohexyl glycerin is 0.1% -0.3%; the solvent makes up 100%. The invention discovers that after oligopeptide-10 and cyclohexylglycerol are combined, the antibacterial effect is greatly improved, and the oligopeptide-10 can still have good inhibition effect on microorganism bacteria such as candida albicans under the condition that the dosage is lower than 50ppm. Meanwhile, the gynecological lotion provided by the invention has obvious advantages in cost because the dosage of the oligopeptide-10 is reduced. In addition, the gynecological lotion provided by the invention also has the effect of obviously repairing the vaginal epithelial cell injury.
Detailed Description
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention. Unless otherwise indicated, all the experimental procedures used in the examples were conventional; the materials, reagents and the like used are all commercially available.
Example 1
The embodiment provides a gynecological lotion, which comprises the following components:
oligopeptide-10: 10ppm of the process comprises,
glycerol: 2 percent,
lactic acid 90%:0.05 percent,
cyclohexylglycerol: 0.2%;
water: the complement is 100 percent.
The embodiment also provides a preparation method of the gynecological lotion, which comprises the following specific steps:
heating purified water as solvent to 90-95deg.C, maintaining the temperature for 30min, sterilizing at high temperature, cooling to below 35deg.C, sequentially adding glycerol, cyclohexylglycerol, and oligopeptide-10 powder, stirring to uniformity, adding lactic acid, and adjusting pH to 4.0-4.3.
Example 2
The embodiment provides a gynecological lotion, which comprises the following components: oligopeptide-10: 2ppm of the process comprises,
glycerol: 2 percent,
lactic acid 90%:0.05 percent,
cyclohexylglycerol: 0.2%;
water: the complement is 100 percent.
The gynecological lotion of this example was prepared in the same manner as in example 1.
Example 3
The embodiment provides a gynecological lotion, which comprises the following components: oligopeptide-10: 5ppm of the total weight of the product,
glycerol: 3 percent,
lactic acid 90%:0.05 percent,
cyclohexylglycerol: 0.2%;
water: the complement is 100 percent.
The gynecological lotion of this example was prepared in the same manner as in example 1.
Example 4
The embodiment provides a gynecological lotion, which comprises the following components: oligopeptide-10: 1ppm of the total weight of the mixture,
glycerol: 1 percent,
lactic acid 90%:0.05 percent,
cyclohexylglycerol: 0.3%;
water: the complement is 100 percent.
The gynecological lotion of this example was prepared in the same manner as in example 1.
Example 5
The embodiment provides a gynecological lotion, which comprises the following components: oligopeptide-10: 30ppm of the process comprises,
glycerol: 5 percent,
lactic acid 90%:0.05 percent,
cyclohexylglycerol: 0.1%;
water: the complement is 100 percent.
The gynecological lotion of this example was prepared in the same manner as in example 1.
Comparative example 1
The comparative example provides a gynecological lotion, which comprises the following formula: oligopeptide-10: 10ppm of the process comprises,
glycerol: 2 percent,
lactic acid 90%:0.05 percent,
cyclohexylglycerol: 0.05%;
water: the complement is 100 percent.
The gynecological lotion of this comparative example was prepared in the same manner as in example 1.
Comparative example 2
The comparative example provides a gynecological lotion, which comprises the following formula: chlorhexidine acetate: the concentration of the water in the water is 500ppm,
glycerol: 2 percent,
lactic acid 90%:0.05 percent,
cyclohexylglycerol: 0.2%;
water: the complement is 100 percent.
The gynecological lotion of this comparative example was prepared in the same manner as in example 1.
Comparative example 3
The comparative example provides a gynecological lotion, which comprises the following formula: oligopeptide-10: 10ppm of the process comprises,
glycerol: 2 percent,
lactic acid 90%:0.05 percent,
benzyl alcohol: 0.2%;
water: the complement is 100 percent.
The gynecological lotion of this comparative example was prepared in the same manner as in example 1.
Experimental example 1
In the experimental example, gynecological lotion provided in examples 1-5 and comparative examples 1-3 is used as an experimental reagent, and the antibacterial rate of the gynecological lotion is detected.
The detection method adopts the' disinfection technical specification (2002 edition), the test condition is stock solution, and the action time is 2 minutes, 5 minutes, 10 minutes and 20 minutes; the antibacterial rate is more than or equal to 50% -90%, which indicates that the product has antibacterial effect; the antibacterial rate is more than or equal to 90%, which indicates that the product has stronger antibacterial effect.
The results are shown in Table 1.
TABLE 1 antibacterial Rate detection results
Experimental example 2
In the experimental example, the gynecological lotion provided in the example 1 is taken as an experimental reagent, and the repairing effect of the gynecological lotion on the epithelial damaged cells is detected.
The detection method comprises the following steps:
18 healthy female rats (body weight 210-240 g) were removed from bilateral ovaries, 6 per group.
Normal control group: 10mL of 0.9% normal saline is injected intravaginally. Infection group and dosing group: test animals were vaginally injected with 10mL of candida albicans ATCC10231 suspension (at a concentration of about 5 x 10 8 cfu/mL), four days of continuous inoculation. On day 5, vaginal secretions of animals from the infected and dosed groups were taken and observed under a microscope to confirm fungal infection in the animals.
Animals in the dosing group were dosed vaginally 1 time, 2mL each time, for 10 consecutive days. Normal control animals and infected animals were vaginally injected 1 time per day with 2mL of 0.9% physiological saline each time. And taking vaginal materials on the 4 th day of stopping the medicine, fixing 4% paraformaldehyde, and then performing HE staining for pathological histology. The number of vaginal mucosal epithelium layers and thickness were calculated.
The results are shown in Table 2.
TABLE 2 detection of repair of epithelial damaged cells
It can be seen that the detection results of the different groupings are significantly different in the rat candida albicans pathogenic model. The gynecological lotion provided by the embodiment of the invention has obvious repairing effect on the vaginal epithelium of the rats infected with candida albicans.
The above examples merely represent a few embodiments of the present invention, which facilitate a specific and detailed understanding of the technical solutions of the present invention, but are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention.
Claims (10)
1. Gynecological lotion, which is characterized by comprising oligopeptide-10 and cyclohexylglycerol; the content of the oligopeptide-10 is 1-30ppm; the content of the cyclohexyl glycerin is 0.1% -0.3%; the solvent makes up 100%.
2. The gynecological lotion according to claim 1, wherein the oligopeptide-10 is present in an amount of 2-10ppm; the content of the cyclohexylglycerol is 0.2%.
3. The gynecological lotion according to claim 1 or 2, further comprising at least one of a humectant, a pH adjustor.
4. A gynecological lotion according to claim 3, wherein the humectant is selected from glycerol, the content of glycerol being 1% -5%, preferably 2% -3%.
5. A gynecological lotion according to claim 3, wherein the pH modifier is selected from lactic acid; and/or the pH value of the gynecological lotion is 4.0-4.3.
6. The gynecological lotion according to any one of claims 1-5, wherein said solvent comprises water.
7. The method for preparing the gynecological lotion according to any one of claims 1 to 6, comprising the steps of:
s1, weighing the components in proportion;
s2, mixing the components; the temperature of the mixing is less than or equal to 35 ℃.
8. Use of a gynecological lotion according to any one of claims 1 to 6 or a gynecological lotion prepared by a preparation method according to claim 7 for bacteriostasis and/or repair of epithelial damaged cells for non-disease treatment purposes.
9. The use according to claim 8, wherein said bacteriostasis comprises inhibition of at least one of the following microbial species: staphylococcus aureus, escherichia coli, candida albicans.
10. The use according to claim 8, wherein the means of bacteriostasis comprises inhibition of microbial bacteria in the environment; alternatively, repairing the epithelial damaged cell comprises repairing the epithelial damaged cell during cell culture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310853837.XA CN117045531A (en) | 2023-07-12 | 2023-07-12 | Gynecological lotion and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310853837.XA CN117045531A (en) | 2023-07-12 | 2023-07-12 | Gynecological lotion and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117045531A true CN117045531A (en) | 2023-11-14 |
Family
ID=88665261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310853837.XA Pending CN117045531A (en) | 2023-07-12 | 2023-07-12 | Gynecological lotion and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117045531A (en) |
-
2023
- 2023-07-12 CN CN202310853837.XA patent/CN117045531A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3098253B1 (en) | Broad spectrum antimicrobial agent | |
| JP6780123B2 (en) | Applications for the preparation of vaginal compositions containing bacteriostatic agents and vaginal compositions | |
| US6348190B1 (en) | Pharmaceutical compositions with antimicrobial activity | |
| CN109010124B (en) | Marine refined gynecological antibacterial gel and preparation method thereof | |
| SE528337C2 (en) | Composition comprising lactic acid and lactoferrin, or a peptide fragment thereof, and use of this composition for treating conditions in the urogenital system | |
| CN111150705A (en) | Alcohol hyaluronic acid disinfectant and preparation method thereof | |
| CN111991417A (en) | Hypochlorous acid gel with physiological responsiveness and application thereof in skin wound surface | |
| CN108619550A (en) | A kind of hydrogel and preparation method thereof | |
| CN117045531A (en) | Gynecological lotion and preparation method and application thereof | |
| CN110575431B (en) | Vaginal acid-base buffer gel and preparation method thereof | |
| CN109464341B (en) | Health care composition | |
| US8568711B2 (en) | Antimicrobial compositions | |
| CN114456239B (en) | Lithospermum and external antibacterial peptide gel preparation prepared from same and application | |
| RU2440122C1 (en) | Preparation accelerating wound healing | |
| CN113632803B (en) | Quaternary ammonium salt complex iodine disinfectant and preparation method thereof | |
| CN111328811B (en) | Low-concentration alcohol sterilization disinfectant and application thereof | |
| CN114209646A (en) | Povidone-iodine temperature-sensitive gel preparation | |
| CN113209202A (en) | Bacteriostatic gynecological lotion and preparation method thereof | |
| EP0347225B1 (en) | Pharmaceutical compositions containing primycin | |
| CN1823753A (en) | Cream for treating beriberi and its production method | |
| CN105796603A (en) | Antibacterial peptide gel and preparation method thereof | |
| CN113198008B (en) | Disinfectant and preparation method and application thereof | |
| CN108938559B (en) | DNA gel sterilization material, preparation method thereof and application of DNA gel sterilization material as sterilization material | |
| CN115607656B (en) | Application of chitosan enzyme and composite gel thereof in preparation of products for preventing or treating skin diseases caused by malassezia | |
| CN111671793B (en) | Production process of sterilized paper towel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |